Literature DB >> 17923131

Evaluation of anti-Müllerian hormone as a test for the prediction of ovarian reserve.

Janet Kwee1, Roel Schats, Joseph McDonnell, Axel Themmen, Frank de Jong, Cornelis Lambalk.   

Abstract

OBJECTIVE: To compare in an integral way the value of the basal serum anti-Müllerian hormone (AMH) level with most of the established ovarian reserve tests.
DESIGN: Prospective randomized controlled trial.
SETTING: Fertility center of a university hospital in the Netherlands. PATIENT(S): One hundred ten patients undergoing their first IVF cycle who were randomized, by a computer-designed four-block system, into two groups. INTERVENTION(S): Fifty-six patients underwent a clomiphene citrate challenge test (CCCT), and 54 patients underwent an exogenous FSH ovarian reserve test (EFORT). In all patients, basal AMH, basal FSH, basal inhibin B, antral follicle count (AFC), and basal volume of the ovaries were measured. In all patients, the test was followed by a standard IVF treatment. MAIN OUTCOME MEASURE(S): Ovarian response after ovarian hyperstimulation in an IVF treatment, expressed as the total number of stimulated follicles, retrieved oocytes, and ongoing pregnancies. RESULT(S): The best prediction of ovarian reserve (Y) was seen in a multiple regression prediction model that simultaneously included AFC, inhibin B increment in the EFORT, and basal volume of the ovaries. Univariate logistic regression showed that the best predictors for poor response were AMH, the CCCT, basal FSH, and the AFC. For hyperresponse, univariate logistic regression showed that the best predictor was AFC. Multiple logistic regression analysis did not produce a better model in terms of improving the prediction of poor response or hyperresponse. The best predictors for the prediction of non-pregnancy were the CCCT and the E(2) increment in the EFORT. CONCLUSION(S): Anti-Müllerian hormone is comparable with other commonly used ovarian reserve tests but is probably most applicable in general practice.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17923131     DOI: 10.1016/j.fertnstert.2007.07.1293

Source DB:  PubMed          Journal:  Fertil Steril        ISSN: 0015-0282            Impact factor:   7.329


  37 in total

1.  Different ovarian response by age in an anti-Müllerian hormone-matched group undergoing in vitro fertilization.

Authors:  Hiroyuki Honnma; Tsuyoshi Baba; Masahiro Sasaki; Yoshiki Hashiba; Hisanori Oguri; Takanori Fukunaga; Toshiaki Endo; Yoshimasa Asada
Journal:  J Assist Reprod Genet       Date:  2011-11-16       Impact factor: 3.412

2.  Impact of cancer therapies on ovarian reserve.

Authors:  Clarisa R Gracia; Mary D Sammel; Ellen Freeman; Maureen Prewitt; Claire Carlson; Anushree Ray; Ashley Vance; Jill P Ginsberg
Journal:  Fertil Steril       Date:  2011-12-02       Impact factor: 7.329

3.  The role of serum AMH and FF AMH in predicting pregnancy outcome in the fresh cycle of IVF/ICSI: a meta-analysis.

Authors:  Lingnv Yao; Wei Zhang; Hong Li; Wenqin Lin
Journal:  Int J Clin Exp Med       Date:  2015-02-15

4.  Reproductive capacity in iron overloaded women with thalassemia major.

Authors:  Sylvia T Singer; Elliott P Vichinsky; Ginny Gildengorin; Jereon van Disseldorp; Mitchell Rosen; Marcelle I Cedars
Journal:  Blood       Date:  2011-07-14       Impact factor: 22.113

5.  Antimüllerian hormone levels are lower in BRCA2 mutation carriers.

Authors:  Lauren Johnson; Mary D Sammel; Susan Domchek; Allison Schanne; Maureen Prewitt; Clarisa Gracia
Journal:  Fertil Steril       Date:  2017-05       Impact factor: 7.329

6.  Antral follicle count determines poor ovarian response better than anti-Müllerian hormone but age is the only predictor for live birth in in vitro fertilization cycles.

Authors:  Mehmet Firat Mutlu; Mehmet Erdem; Ahmet Erdem; Sule Yildiz; Ilknur Mutlu; Ozgur Arisoy; Mesut Oktem
Journal:  J Assist Reprod Genet       Date:  2013-03-19       Impact factor: 3.412

7.  Anti-müllerian hormone levels as a predictor of the pregnancy rate in women of advanced reproductive age.

Authors:  Sezai Sahmay; Mahmut Oncul; Abdullah Tuten; Abdullah Tok; Abdullah Serdar Acıkgoz; Ismail Cepni
Journal:  J Assist Reprod Genet       Date:  2014-09-04       Impact factor: 3.412

8.  Anti-Mullerian hormone and antral follicle count as predictors for embryo/oocyte cryopreservation cycle outcomes in breast cancer patients stimulated with letrozole and follicle stimulating hormone.

Authors:  Sanghoon Lee; Sinan Ozkavukcu; Elke Heytens; Fred Moy; Rose M Alappat; Kutluk Oktay
Journal:  J Assist Reprod Genet       Date:  2011-05-04       Impact factor: 3.412

Review 9.  Diagnosis and treatment of infertility-related male hormonal dysfunction.

Authors:  Martin Kathrins; Craig Niederberger
Journal:  Nat Rev Urol       Date:  2016-04-19       Impact factor: 14.432

10.  Antimüllerian hormone and antral follicle count are lower in female cancer survivors and healthy women taking hormonal contraception.

Authors:  Lauren N C Johnson; Mary D Sammel; Katherine E Dillon; Lara Lechtenberg; Allison Schanne; Clarisa R Gracia
Journal:  Fertil Steril       Date:  2014-06-14       Impact factor: 7.329

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.